<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Glaucoma Treatment on FinanClub</title>
    <link>https://finan.club/tags/glaucoma-treatment/</link>
    <description>Recent content in Glaucoma Treatment on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 24 Jan 2024 09:05:58 +0000</lastBuildDate><atom:link href="https://finan.club/tags/glaucoma-treatment/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GKOS</title>
      <link>https://finan.club/us/gkos/</link>
      <pubDate>Wed, 24 Jan 2024 09:05:58 +0000</pubDate>
      
      <guid>https://finan.club/us/gkos/</guid>
      <description>score:12
Chances: Glaukos Corporation continues to benefit from a robust product portfolio and favorable clinical trial results. The FDA approval of Glaukos&amp;rsquo; iDose TR is likely to reshape glaucoma care, promising proactive and durable treatment. Risks: The insider transaction and sale of shares by the President &amp;amp; COO could raise concerns among investors.</description>
    </item>
    
  </channel>
</rss>
